Loading..
  • SynAct Pharma logoSVE
  • SynAct Pharma logoENG
  • About us
    • The Company in brief
    • Vision
    • Mission
    • History
    • Organisation
    • Collaborations and Partnerships
  • Our Science
    • Resolving Inflammation
    • The Melanocortin System and Inflammation
    • SynAct’s Technology – Selective Melanocortin Stimulation
    • Scientific Advisory Board
  • Pipeline
    • Pipeline Overview
    • The AP1189 Development Program
      • Rheumatoid Arthritis
      • Membranous Nephropathy
      • Virus Induced Respiratory Insufficiency
    • Peptide Agonists
      • TXP-11
    • Ongoing clinical studies
  • Investors
    • Capital Markets Day 2023
    • Listing Nasdaq 2022
    • Rights Issue 2022
    • Word from the CEO
    • Financial Reports
    • Investment highlights
    • Presentations
    • The Share
      • Share price development
      • Ownership Structure
      • Insiders
      • Share Capital Development
    • Analyst Coverage
    • Calendar
    • Press Releases
    • Prospectuses
  • Governance
    • General Meetings
    • Corporate Governance Report
    • Nomination Committee
      • Nomination Committee 2023
    • Board of Directors
      • Remuneration Committee
      • Audit Committee
      • R&D Committee
    • Management
    • Auditor
    • Articles of Association
    • Code of Conduct
  • Media
    • Press Releases
    • Synact in Media
    • Image Bank
    • Subscribe
  • Contact

Financial Reports

Interim reports
  • Annual reports
  • All categories
All years
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • All years
May 5, 2023

SynAct Pharma publishes Q1 2023 interim report

February 17, 2023

SynAct Pharma publishes Annual Results for 2022

November 4, 2022

SynAct Pharma publishes Q3 2022 interim report

August 5, 2022

SynAct Pharma publishes Q2 2022 interim report

May 30, 2022

SynAct Pharma publishes Q1 2022 interim report

February 11, 2022

Annual Results 2021

November 12, 2021

Interim report Q3 2021

August 27, 2021

SynAct Pharma: Interim Report January-June 2021 August 27, 2021 (Q2 2021 Report included)

May 5, 2021

SynAct Pharma: Interim report January-March 2021

February 12, 2021

Year-end Report 2020

November 13, 2020

SynAct Pharma publishes Q3 2020 interim report (in Swedish)

August 28, 2020

SynAct Pharma publishes Q2 2020 interim report (in Swedish)

May 5, 2020

SynAct Pharma publishes Q1 2020 interim report (in Swedish)

February 11, 2020

SynAct Pharma publishes Annual Results for 2019 (in Swedish)

November 15, 2019

SynAct Pharma publishes Q3 2019 interim report (in Swedish)

August 30, 2019

SynAct Pharma publishes Q2 2019 interim report (in Swedish)

April 24, 2019

SynAct Pharma publishes Q1 2019 interim report (in Swedish)

February 11, 2019

Year-end report for the financial year 2018

November 16, 2018

Interim report Q3 2018

August 30, 2018

Interim report 01/01/2018 – 30/06/2018

April 19, 2018

SynAct Pharma publishes Q1-2018 Report

February 13, 2018

Year-end report 2017

November 3, 2017

Interim report Q3 2017

August 31, 2017

Half-yearly report 01-01-2017 – 30-06-2017

May 11, 2017

Interim report Q1 2017   Synact Pharma

February 9, 2017

SynAct Pharma Year-end report 2016

November 4, 2016

Interim report 3, 2016

August 31, 2016

Half-yearly Report 2016

  • Investors
    • Capital Markets Day 2023
    • Listing Nasdaq 2022
    • Rights Issue 2022
    • Word from the CEO
    • Financial Reports
    • Investment highlights
    • Presentations
    • The Share
      • Share price development
      • Ownership Structure
      • Insiders
      • Share Capital Development
    • Analyst Coverage
    • Calendar
    • Press Releases
    • Prospectuses
Torbjørn Bjerke
Torbjørn Bjerke
Chief Executive Officer
+46 727 44 41 58
[email protected]
Patrik Renblad, MSc.
Patrik Renblad, MSc.
Chief Financial Officer
+4670 747 97 68
[email protected]

About Synact Pharma

SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation with melanocortin biology. Selective activation of the melanocortin system can help the immune system resolve excessive or chronic inflammation.

  • Privacy Policy
  • Cookies

Explore our Website

  • About us
  • Our Science
  • Pipeline
  • Investors
  • Governance
  • Media
  • Contact
  • LinkedIn

Subscribe